In this randomized, double-blind, double dummy parallel group trial, the efficacy and safety of once daily oral administration of the fixed dose combination (FDC) of linagliptin/pioglitazone will be investigated in type 2 diabetic patients with insufficient glycaemic control.
Qualified Participants Must:
Have a diagnosis of type 2 diabetes mellitus prior to informed consent
Have insufficient glycaemic control (HbA1c ≥ 7.0 to≤ 10.5% at Visit 2) on diet and exercise alone, without oral antidiabetic drug therapy within 10 weeks prior to start of the run-in period (date of Visit 2)
Be 18-80 years of age at start date of Visit 1 (Screening)
Have BMI ≤ 45 kg/m2 (Body Mass Index) at start date of Visit 1 (Screening)
Qualified Participants May Receive:
Stipend for participation and time.